All treatments
Treatment
TransCon TLR7/8 Agonist clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
This study looks at new ways to treat a type of head and neck cancer before surgery. It's testing new medicines, alone or together, to see if they can shrink the cancer effectively. This could help improve treatment for people with this specific cancer.
For: Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Spain · Hungary · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
This study is testing a new cancer medicine, TransCon TLR7/8 Agonist, sometimes given with another drug called Keytruda. It's for adults with advanced cancer. Researchers want to see if it's safe, what dose works best, and if it can shrink tumours.
For: CancerSpain · Netherlands